bluuebunny/crossref_metadata_2025_split huggingface dataset:
244-LB: Glutamate Is Associated with Type 2 Diabetes through PLG Regulation
Authors: LEE HYO JUNG , YUN JI HO , KIM HYO-JIN , JANG HAN BYUL , PARK SANG IK , LEE HYE-JA 
Published: June 2019

Glutamate is a major excitatory neurotransmitter and is involved in the ER stress and β-cell dysfunction, which are important clinical features of diabetes mellitus. However, metabolic studies of diabetes in relation to glutamate are not well understood. In this regard, we tried to search for the function of glutamate in type 2 diabetes. We found that glutamate levels were significantly increased in both prediabetic and diabetic participants in 10 years follow-up study (Korean Genome and Epidemiology Study: Ansan-Ansung cohort). And also, we observed that glutamate is associated with FERM domain-containing protein 4B (FRMD4B), plasminogen (PLG) and partitioning-defective 3 (PARD3) by genome-wide association studies (GWAS). Among them, PLG levels were not only significantly increased by palmitate treatment, which is general model for induction of insulin resistance, but also increased by glutamate treatment. To demonstrate the association between PLG and type 2 diabetes, we treated thapsigargin (ER stress) or oligomysin (mitochondrial dysfunction) in Sk-Hep I cells, and observed that PLG levels were significantly increased in these conditions. Consistently, PLG overexpression increased expression of ER stress-related factors; however, repression of PLG expression by plg siRNA attenuated these changes. Our results demonstrate that high levels of glutamate are associated with development of diabetes, and are assumedly regulated by PLG.

Disclosure
H. Lee: None. J. Yun: None. H. Kim: None. H. Jang: None. S. Park: None. H. Lee: None.

Funding
Korea National Institute of Health (2017-NG64001-02)
2446-PUB: To What Extent Does Hyperglycemia Affect Bone Metabolism?
Authors: HAYASHI SEIKO , DESHPANDE GAUTAM , NOTO HIROSHI 
Published: June 2019

Background: Chronic hyperglycemia has been previously reported to affect bone metabolism. However, this association may also be affected by other factors surrounding the hyperglycemic state, including physiologic complications of diabetes mellitus and its treatments. This study aims to assess to what extent hyperglycemia itself affects bone metabolism, using HbA1c as an indicator for chronic hyperglycemia.
Methods: We retrospectively examined data on all patients older than 20 years old who visited St. Luke’s Hospital for annual health checkup from April 2004 to March 2017. T scores were measured by forearm Dual-energy X-ray absorptiometry (DXA). Longitudinal analysis was used for statistical analyses, using multi-level mixed effect modeling treating T scores as a time-dependent variable to calculate beta coefficients, based on a T score range of HbA1c 5.5- 6.4. Data were adjusted for age, BMI, alcohol consumption, smoking, and exercise.
Results: 129,295 patients (mean age, 45.3 ±12.5 years; mean BMI, 22.3 ±3.39 kg/m2; male, 49.1%) were included over a median follow-up time of 744 days. Mean T score value was 99.1±12.3%. In longitudinal regression for men, T scores of HbA1c &lt;=5.4 and HbA1c 6.5-8.4 were significantly low (βcoefficient -0.58- -0.14, P&lt;0.05). In women under 50 years old, T scores in HbA1c range of 4.5-5.4 were significantly high (βcoefficient 0.19, P&lt;0.05); T scores in a HbA1c range of 6.5-7.4 were significantly low (βcoefficient -0.60, P&lt;0.05). In women &gt;= 50 years, T scores in a HbA1c range of 4.5-5.4 were significantly high (βcoefficient 0.15, P&lt;0.05), while T scores of HbA1c &gt;=6.5 were significantly low (βcoefficient -1.80- -0.57, P&lt;0.05).
Conclusion: Both men and women tend to have low bone mineral density at HbA1c values &gt;= 6.5. Especially in women older than 50 years, bone mineral density significantly decreases as the value of HbA1c increases.

Disclosure
S. Hayashi: None. G. Deshpande: None. H. Noto: None.
2456-PUB: Cholesterol Uptake Capacity of High-Density Lipoprotein Predicts the Risk of Future Diabetes: The Hisayama Study
Authors: HIRAKAWA YOICHIRO , TOH RYUJI , HIGASHIOKA MAYU , YOSHINARI MASAHITO , HONDA TAKANORI , YOSHIDA DAIGO , HATA JUN , NAKAMURA UDAI , KITAZONO TAKANARI , NINOMIYA TOSHIHARU 
Published: June 2019

Background: Cholesterol uptake capacity (CUC) is a novel index of the functionality of serum high-density lipoprotein (HDL), which has been reported to be associated with insulin resistance and the cardiovascular risk. However, only a few studies investigated the association of CUC with the development of diabetes. Herein, we assessed the association of CUC with incident type 2 diabetes in a general Japanese population.
Methods: A total of 2,162 subjects aged 40-79 years without diabetes underwent comprehensive health examination including 75g OGTT and were followed-up prospectively for a median of 6.0 years. The amount of HDL-contained cholesterol per apolipoprotein A1 levels after incubating the participants’ HDL with cholesterol as CUC were measured at baseline. CUC levels were categorized into quartiles (Q1:&lt;0.303, Q2:0.303-0.325, Q3:0.326-0.351, Q4:≥0.352 a.u.). The hazard ratios (HRs) and their 95% confidence intervals (CIs) of CUC levels on the incident diabetes were estimated by using a Cox’s proportional hazard model with adjustment for confounding factors.
Results: During the follow-up period, 219 subjects experienced diabetes. The multivariable-adjusted HR (95% CI) was significantly decreased with elevating levels of CUC: 1.00 (reference) in Q1, 0.83 (0.57, 1.20) in Q2, 0.77 (0.52, 1.14) in Q3 and 0.64 (0.42, 0.98) in Q4 (p=0.04 for trend). In the analysis combined serum HDL cholesterol level (≤50mg/dl [25 percentile value] vs. &gt;51 mg/dl) and CUC (Q1-Q3 vs. Q4), HRs (95% CIs) for the incident diabetes compared to both low group were 0.72 (0.36, 1.45) in isolated high CUC group, 0.73 (0.50, 1.06) in isolated high HDL cholesterol group, and 0.56 (0.34, 0.93) in both high group (p=0.88 for interaction).
Conclusion: Our findings suggest that the risk of diabetes decreased with elevating CUC levels independent of HDL cholesterol levels in the general Japanese population.

Disclosure
Y. Hirakawa: None. R. Toh: Other Relationship; Self; Sysmex Corporation. M. Higashioka: None. M. Yoshinari: None. T. Honda: None. D. Yoshida: None. J. Hata: None. U. Nakamura: None. T. Kitazono: None. T. Ninomiya: Research Support; Self; Asahi Kasei Corporation, Denka Company Limited, DeSC Healthcare, Inc, Mochida Pharmaceutical Co., Ltd., Suntory Beverage & Food Limited, Sysmex Corporation.

Funding
Japan Ministry of Education, Culture, Sports, Science and Technology; Japan Ministry of Health, Labour and Welfare; Japan Agency for Medical Research and Development
2457-PUB: Microcirculatory Alterations Are Associated with Increased Risk of Total Death in Patients with Type 2 Diabetes
Authors: OKADA HIROSHI , OKADA YUKI , FUKUI MICHIAKI 
Published: June 2019

Rationale and Objective: It has been well known that patients with diabetes had shorter life expectancy, compared to patients without diabetes. Although several studies have been reported the significance of microciculatory dysfunction particularly in the early phase of critical illness, it has been not reported the association between microcirculatory dysfunction and long-term prognosis. Therefore, we evaluated the relationship between microcirculatory dysfunction and the risk of total death in patients with type 2 diabetes.
Methods: A total of 1017 patients with diabetes (657 men and 360 women), who were admitted to the department of internal medicine from September 2015 to December 2017, were included in this study. We measured perfusion index (PI), which could reflect microcirculation, using a pulse oximeter (Masimo Radical 7; Masimo Corp., Irvine, CA, U.S.) on the day of admission. Cox proportional hazards models was used in multivariate analysis.
Results: The median duration of follow-up was 670.0 days and a total of 117 patients died during follow-up duration. The average age, HbA1c and PI value was 71.0 ± 11.6 years, 7.7 ± 1.9% and 3.2 ± 2.4%. PI value was negatively correlated with age (β = -0.18, P &lt; 0.0001), pulse rate (β = -0.06, P = 0.04) and serum creatinine (β = -0.16, P &lt; 0.0001). PI value was positively correlated with body mass index (β = 0.11, P = 0.0007) and hemoglobin level (β = 0.19, P &lt; 0.0001). Adjusted Cox regression analyses demonstrated that PI value was associated with an increased hazard of total death; hazard ratios were 1.11 (95% confidence interval, 1.01 - 1.23).
Conclusion: The present study indicates the importance of microciculatory dysfunction and monitoring as a potential independent prognostic factor of mortality in patients with type 2 diabetes.

Disclosure
H. Okada: None. Y. Okada: None. M. Fukui: Research Support; Self; Astellas Pharma Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Company, Johnson & Johnson, Kyowa Hakko Kirin Co., Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Sanofi, Sanwa Kagaku Kenkyusho, Takeda Pharmaceutical Company Limited. Speaker's Bureau; Self; AstraZeneca, Eli Lilly and Company, Kowa Pharmaceutical Europe Co. Ltd., Kyowa Hakko Kirin Co., Ltd., Merck & Co., Inc., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Inc., Ono Pharmaceutical Co., Ltd., Sanofi, Sanwa Kagaku Kenkyusho, Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited.
246-OR: Contribution of Plasma Glucose and Hormones to the Acute Compensatory Rise in Endogenous Glucose Production (EGP) during Glucosuria in T2D Patients
Authors: ALATRACH MARIAM , AGYIN CHRISTINA , LAICHUTHAI NITCHAKARN , ADAMS JOHN M. , ABDUL-GHANI MUHAMMAD , TRIPLITT CURTIS L. , DEFRONZO RALPH A. , CERSOSIMO EUGENIO 
Published: June 2019

Aim: To examine the role of plasma glucose (GLU), insulin (INS) and glucagon (GG) changes in EGP stimulation during glucosuria (UGE) following SGLT2i administration.
Methods: Using tracer (3-3H-glucose), 30 T2D patients (Age=55±1y, BMI=32.2±0.7kg/m2, FPG=140±6mg/dl, A1c=7.3±0.1%) received three 300-min procedures at 2-weeks intervals: (I) control clamp (CON) with no glucose/hormone infusions; (II) pancreatic clamp (PAN) with somatostatin (0.75mg/h), basal replacement of insulin (0.1mU/kg.min) and glucagon (0.3ng/kg.min); (III) isoglycemic clamp (ISO) with variable dextrose infusion to maintain GLU equal to baseline. Prior to start of each clamp subjects received placebo (PCB, n=10) or dapagliflozin 10mg (DAPA, n=20).
Results: After DAPA (CON), INS decreased (-7±1µU/ml) while GG increased (+10±1pg/ml) (both p&lt;0.05 vs. PCB). Despite UGE of 0.48mg/kg.min, GLU decline was modest (-31±1) due to a “paradoxical” rise in EGP after DAPA. During PAN with DAPA and PCB, INS and GG were unchanged from baseline, and EGP stimulation in DAPA compared to PCB still increased, yet GLU decline was modest (-28.4±3.0). During ISO, EGP decreased markedly with DAPA as well as PCB despite similar plasma GG and INS concentrations.
Conclusion: DAPA-induced glucosuria stimulation of EGP cannot be entirely explained by the rise in plasma glucagon or decline in plasma insulin.

Disclosure
M. Alatrach: None. C. Agyin: None. N. Laichuthai: None. J.M. Adams: None. M. Abdul-Ghani: None. C.L. Triplitt: Consultant; Self; Abbott. Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc. R.A. DeFronzo: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Elcelyx Therapeutics, Inc., Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Novo Nordisk Inc. Research Support; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc. Speaker's Bureau; Self; AstraZeneca, Novo Nordisk Inc. E. Cersosimo: None.
2463-PUB: Prevalence of Metabolic Syndrome in Patients with Type 1 Diabetes: Impact on Microvascular Complications and Subclinical Inflammation
Authors: LECUMBERRI EDURNE , LUQUE-RAMÍREZ MANUEL , QUIÑONES SILVA JHONATAN , FERNÁNDEZ ELENA , DIAZ SARA ALONSO , ESCOBAR-MORREALE HÉCTOR FRANCISCO , NATTERO-CHÁVEZ LÍA 
Published: June 2019

Introduction: The MS might also be present in patients with DM1 worsening vascular prognosis.
Objective: We aimed to determine the prevalence of MS and its association with microvascular disease and to describe the differences between patients with or without MS in markers of subclinical inflammation and adiposity.
Methods: A cross-sectional study including 289 consecutive patients with DM1. MS was defined according to the criteria of the IDF but for the presence of fasting hyperglycemia or diabetes. Microvascular complications were assessed according to ADA. Serum inflammation markers such as high hsCRP, ESR, homocystein and fibrinogen were measured.
Results: The mean age was 36 ± 12 years-old. 40% were female. Duration of DM1 was 20 ± 11 years. The mean HbA1c was 7.6±1.3% and the GFR was 94±18 ml/min/1.73m2. The prevalence of MS, as defined, was 12.5% (95% CI: 9.1 - 16.8). The odds of having microvascular complications was 2.4 higher among MS+ group [OR: 2.4 (1.0-5.7); P = 0.042] compared with MS- group, after adjusting for age and DM1 duration. Adiposity and markers of subclinical inflammation were significantly higher in MS+ group compared to their MS- counterparts (Table 1).
Conclusions: The prevalence of MS was considerable in patients with DM1. MS was an independent risk factor for the presence of microvascular complications regardless of age and DM1 duration. The presence of MS in patients with DM1 is associated with adiposity and subclinical inflammation.

Disclosure
E. Lecumberri: None. M. Luque-Ramírez: None. J. Quiñones Silva: None. E. Fernández: None. S. Alonso Diaz: None. H. Escobar-Morreale: None. L. Nattero-Chávez: None.

Funding
Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness (PI1400649, PI151686, PIE1600050)
248-OR: Empagliflozin and Cardiorenal Outcomes in Patients with Nonproteinuric Kidney Disease in the EMPA-REG OUTCOME Trial
Authors: INZUCCHI SILVIO E. , ZINMAN BERNARD , GEORGE JYOTHIS , MATTHEUS MICHAELA , EYNATTEN MAXIMILIAN VON , WANNER CHRISTOPH , HAUSKE SIBYLLE 
Published: June 2019

Proteinuria in chronic kidney disease (CKD) is a strong risk predictor for adverse cardiorenal outcomes. However, non-proteinuric CKD in type 2 diabetes (T2D) is rarely studied in clinical trials despite epidemiological evidence indicating a recent shift towards this phenotype. We explored the effect of empagliflozin (EMPA) on cardiorenal outcomes in a subgroup of patients from EMPA-REG OUTCOME with non-proteinuric CKD at baseline. 7020 patients with T2D and prior CV disease were treated with EMPA 25mg, 10mg or placebo (PBO) (median follow-up of 3.1 years). Post hoc, Cox regression assessed effects of EMPA vs. PBO on the composite outcome of CV death/HHF, CV death, HHF, a composite kidney outcome of incident/worsening nephropathy and all-cause mortality. Non-proteinuric CKD was defined as low eGFR and absence of overt albuminuria (eGFR &lt;60 ml/min/1.73m2 and UACR &lt;300 mg/g). Overall, 1290 (18.4%) met this criterion. In this exploratory analysis, beneficial effects of EMPA vs. PBO on cardiorenal outcomes were consistent in patients with T2D and non-proteinuric CKD as compared to all other patients. This result suggests that absence of overt proteinuria may not alter the cardiorenal treatment response to EMPA. The ongoing EMPA-KIDNEY study investigates effects of EMPA on cardiorenal outcomes in a broad CKD population with and w/o diabetes including patients with lower proteinuria levels.

Disclosure
S.E. Inzucchi: Consultant; Self; vTv Therapeutics, Zafgen, Inc. Other Relationship; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Lexicon Pharmaceuticals, Inc., Novo Nordisk A/S, Sanofi. B. Zinman: Advisory Panel; Self; Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc. Consultant; Self; Abbott, AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Janssen Pharmaceuticals, Inc., Merck & Co., Inc., Novo Nordisk Inc. J. George: Employee; Self; Boehringer Ingelheim International GmbH. M. Mattheus: Employee; Self; Boehringer Ingelheim Pharma GmbH&Co.KG. M. von Eynatten: Employee; Self; Boehringer Ingelheim International GmbH. C. Wanner: Advisory Panel; Self; Bayer AG, Boehringer Ingelheim International GmbH, Merck Sharp & Dohme Corp. Board Member; Self; Boehringer Ingelheim International GmbH. Speaker's Bureau; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Lilly Diabetes, Mitsubishi Tanabe Pharma Corporation. S. Hauske: Employee; Self; Boehringer Ingelheim International GmbH.

Funding
Boehringer Ingelheim; Eli Lilly and Company
2487-PUB: Purinergic Regulation of Adiponectin Exocytosis and the Role of Sympathetic Innervation for Adiponectin Secretion
Authors: MUSOVIC SALIHA , KOMAI ALI M. , MICALLEF PETER , WU YANLING , ASTERHOLM INGRID WERNSTEDT , OLOFSSON CHARLOTTA S. 
Published: June 2019

The white adipocyte hormone adiponectin improves insulin sensitivity and has a protective role in the development of type 2 diabetes. The rapid incidence of obesity-associated disorders emphasizes the importance of understanding the regulation of adiponectin secretion. Hormones are typically secreted via regulated exocytosis but the mechanisms controlling adiponectin release remains inadequately investigated. We have previously demonstrated that catecholamines/cAMP trigger adiponectin exocytosis via activation of adrenergic beta-3-receptors (β3ARs) and Epac1, while elevations of intracellular Ca2+ potentiate the exocytotic process. White adipose tissue is highly innervated by sympathetic nerves, co-releasing norepinephrine (NE) and ATP, thus suggesting a role of the sympathetic nervous system in regulation of adiponectin secretion. Here we have studied the role of sympathetic innervation and purinergic signaling in adiponectin release. Extracellular NE triggered adipocyte exocytosis, whereas extracellular ATP potentiated NE-triggered adipocyte exocytosis. Short-term adiponectin secretion was stimulated by NE while ATP augmented the catecholamine-stimulated release. The effect of ATP was abolished in adipocytes pre-treated with a P2Y2-receptor antagonist. In adipocytes isolated from obese/diabetic mice, ATP-induced adiponectin release was abrogated together with a reduced gene expression of the P2Y2-receptor. Moreover, white adipose tissue content of NE and tyrosine hydroxylase was reduced in obese/diabetic mice. We propose that the physiological stimulatory pathway for adiponectin exocytosis is via sympathetic innervation, co-releasing NE and ATP which activates β3ARs (elevates cAMP) and P2Y2Rs (increases Ca2+). We also suggest that decreased NE and ATP release within the adipose tissue together with disrupted adipocyte purinergic signaling results in disturbed adiponectin release in diabetic/obese conditions.

Disclosure
S. Musovic: None. A.M. Komai: None. P. Micallef: None. Y. Wu: None. I. Wernstedt Asterholm: None. C.S. Olofsson: None.
249-OR: Empagliflozin Selected Cardiovascular and Safety Outcomes in Routine Care: First Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
Authors: PATORNO ELISABETTA , PAWAR AJINKYA , FRANKLIN JESSICA , NAJAFZADEH MEHDI , DERUAZ-LUYET ANOUK , BRODOVICZ KIMBERLY , SAMBEVSKI STEVEN , BESSETTE LILY G. , KULLDORFF MARTIN , SCHNEEWEISS SEBASTIAN 
Published: June 2019

EMPRISE studies the effectiveness, safety and healthcare utilization of empagliflozin (EMPA), a SGLT2 inhibitor, using data from Medicare and 2 U.S. commercial claims datasets (2014-2019). In an analysis on data from 2014-2016, we identified 17,551 pairs of 1:1 propensity score-matched patients ≥18 years with type 2 diabetes initiating EMPA or a DPP-4 inhibitor (DPP-4i). We assessed a composite CV outcome (MI, stroke, or all-cause mortality) and an extended CV outcome (plus heart failure hospitalization or coronary revascularization). Safety outcomes of interest were lower-limb amputations, bone fractures, diabetic ketoacidosis (DKA), and acute kidney injury. We estimated pooled HR and 95% CI adjusting for &gt;140 baseline covariates. Compared to DPP-4i, EMPA was associated with a trend to lower risk of the CV outcome [HR (95% CI) = 0.82 (0.62-1.10)], and a lower risk of the extended CV outcome [0.73 (0.60-0.88)], heart failure hospitalization [0.56 (0.43-0.73)]. Risk of safety outcomes were in line with current evidence despite small numbers, Table 1. We observed a numerical increase in DKA risk [1.74 (0.84-3.58)]. Early findings from EMPRISE showed that compared with DPP-4i, EMPA was associated with a lower risk of CV outcomes with varying levels of precision, and a safety profile consistent with currently documented information.

Disclosure
E. Patorno: Research Support; Self; National Institute on Aging. Other Relationship; Self; Boehringer Ingelheim International GmbH. A. Pawar: None. J. Franklin: Research Support; Self; U.S. Food and Drug Administration. M. Najafzadeh: Consultant; Self; Epigenomics. A. Deruaz-Luyet: Employee; Self; Boehringer Ingelheim International GmbH. Employee; Spouse/Partner; Medtronic, Sanofi. K. Brodovicz: Employee; Self; Boehringer Ingelheim Pharmaceuticals, Inc. S. Sambevski: Employee; Self; Boehringer Ingelheim International GmbH. L.G. Bessette: None. M. Kulldorff: None. S. Schneeweiss: Consultant; Self; Aetion, WHISCON, LLC.

Funding
Boehringer Ingelheim
2490-PUB: The Relationship between Circulatory Levels of Fractalkine, Omentin, and the Mass of Adipose Tissue and Their Role in the Pathogenesis of Diabetes Mellitus Type 2
Authors: LAVRYNENKO OLGA , KRAVCHUN NONNA , MISURA KATHERINE , ZEMLIANITSYNA OLHA , DUNAEVA INNA , KRAVCHUN PAVLO , DEFRONZO RALPH A. , CERSOSIMO EUGENIO , KARACHENTSEV IURIY 
Published: June 2019

Objective: To examine the extent to which circulating levels of omentin and fractalkine are dependent on the degree of adipose tissue accumulation, waist circumference, plasma insulin and НО??-IR in representatives of Ukrainian population.
Materials and Methods: 250 individuals mean age of 65.48±11.86 years were examined; waist circumference was measured; adipose tissue mass was assessed by bio-impedance with relative body weight. Content of insulin, blood fractalkine and omentin were determined by immune enzyme method and НО??-IR index was calculated.
Results: There was an inverse correlation between blood fractalkine and omentin levels(r = -0.863, p&lt;0.001). Blood fractalkine level correlates positively with adipose mass of the body(r=0.5341, p&lt;0.001)); waist circumference- (r =0.4542, p&lt;0.001); insulinemia (r =0.7798, p&lt;0.001) and НО??-IR levels (r= 0.745, p&lt;0.001). Omentin level correlates negatively with adipose body mass(r = -0.609, p&lt;0.001); waist circumference- (r = -0.397, p&lt;0.001); insulinemia (r = -0.799, p&lt;0.001) and НО??-IR levels (r = -0.7706, p&lt;0.001). The data also showed that accumulation of adipose mass greater than 25% of total body mass determines an increase in blood fractalkine levels up to750 ng/mL and higher, and НО??-IR&gt; 2.77 is associated with decreased omentin levels down to500 ng/mL and less.
Conclusion: These data indicate strong associations, which suggest that there may be an important role for fractalkine and omentin in markers of diabetes mellitus and obesity.

Disclosure
O. Lavrynenko: None. N. Kravchun: None. K. Misura: None. O. Zemlianitsyna: None. I. Dunaeva: None. P. Kravchun: None. R.A. DeFronzo: Advisory Panel; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Elcelyx Therapeutics, Inc., Intarcia Therapeutics, Inc., Janssen Pharmaceuticals, Inc., Novo Nordisk Inc. Research Support; Self; AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Janssen Pharmaceuticals, Inc., Merck & Co., Inc. Speaker's Bureau; Self; AstraZeneca, Novo Nordisk Inc. E. Cersosimo: None. I. Karachentsev: None.